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Abstract 
Flavonoids are a group of phytochemicals ubiquitously present in vegetables, fruits, berries 
and herbs. It is suggested that they contribute to protection against several lifestyle diseases 
including cancer. Nevertheless, herbal extracts and foods rich in certain flavonoids have been 
shown to interact with the metabolism of drugs that may cause adverse effects. The interac-
tions are often due to modulation of drug metabolising cytochrome P450 enzymes in the liver.  
The present study examined inhibitory effects of the flavonoid quercetin on the cyto-
chrome P450 isoform CYP2E1. Quercetin, myricetin and isorhamentin were flavonoids inves-
tigated for inhibitory effects on the isoform CYP3A4. The metabolising function of those spe-
cific cytochrome P450 isoforms is crucial for detoxification and/or bioactivation of foreign 
compounds. Catalytic activity was measured in vitro using human liver microsomes separated 
in male and female pools. Reversibility of enzyme inhibition was investigated and kinetic 
measurements were performed in order to determine inhibition mechanism. Based on results 
from animal experiments, the hypothesis was that the selected flavonoids inhibit enzyme ac-
tivity and that the degree of inhibition differed between genders.  
Quercetin inhibited CYP2E1 activity and quercetin and myricetin inhibited CYP3A4 activ-
ity as expected, but isorhamnetin had no inhibitory effects on CYP3A4. Inhibition was re-
versible in all enzyme pools, but the mechanism varied between competitive, uncompetitive 
and non-competitive inhibition. These observations are related to the flavonoid structure 
where the number and position of hydroxyl-groups determine the binding mechanism to the 
enzyme and thereby the level and mode of inhibition. Surprisingly, this study revealed no sub-
stantial gender disparities of flavonoid inhibition in human cytochrome P450 activity. Large 
variations between enzyme pools were observed within the same gender, suggesting inter-in-
dividual differences attributable to genetic and/or other lifestyle factors rather than gender.  
This study provided gained insight in human cytochrome 450 regulation in presence of fla-
vonoids and the results can contribute to research in drug development.  
 
Keywords: Cytochrome P450, CYP450, CYP2E1, CYP3A4, Flavonoid, Quercetin, Myricetin, Isorhamnetin, food-
drug interactions, FDI 
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Sammanfattning 
Flavonoider är en grupp fytokemikalier som finns i de flesta grönsaker, frukt bär och örter. De 
har visat sig bidra till ett skydd mot flera livsstilssjukdomar, till exempel cancer. Örtextrakt 
och livsmedel med högt innehåll av vissa flavonoider har dock visat sig påverka nedbryt-
ningen av läkemedel vilket kan orsaka oönskade biverkningar. Interaktionen involverar fram-
förallt en kemisk modulering av läkemedelsnedbrytande, så kallade cytokrom P450-enzymer i 
levern.  
Den här studien undersökte inhibering av flavonoiden quercetin på cytokromisoformen 
CYP2E1 samt flavonoiderna quercetin, myricetin och isorhamnetin på CYP3A4. Aktiviteten 
hos dessa cytokrom P450-isoformer utgör en vital funktion i nedbrytningen av främmande 
ämnen. Katalytisk aktivitet mättes in vitro i levermikrosomer från människor uppdelade i 
manliga och kvinnliga pooler. Inhiberingens reversibilitet undersöktes och kinetiska analyser 
utfördes för att ta reda på inhiberingsmekanismen. 
Hypotesen, baserad på resultat från liknande djurstudier, var att de specifika flavonoiderna 
inhiberar enzymaktivitet och att inhiberingsgraden varierar mellan könen.  
Resultaten visade att quercetin inhiberade CYP2E1 aktivitet och quercetin, myricetin inhi-
berade CYP3A4 aktivitet som förväntat, men isorhamnetin inhiberade inte CYP3A4. Inhibe-
ringen var reversibel i alla enzympooler och typen av inhibering var antingen kompetitiv, 
okompetitiv eller icke-kompetitiv. Dessa observationer kan relateras till flavonoidernas ke-
miska struktur där antalet hydroxylgrupper och dess positioner avgör bindningen till enzymet 
och därav graden av inhibering.  Den här studien visade dock inga väsentliga skillnader mel-
lan könen i flavonoidernas förmåga att inhibera cytokrom P450-aktivitet i människor. Det var 
stor variation mellan enzympoolerna inom samma kön vilket tyder på interindividuella skill-
nader relaterade till genetiska eller andra livsstilsfaktorer snarare än kön.  
Resultaten från studien kan bidra till ökad kunskap om cytokrom-P450-reglering i männi-
ska vilket kan stödja forskning inom läkemedelsutveckling.  
 
Nyckelord: Cytokrom P450, CYP450, CYP2E1, CYP3A4, Flavonoid, Quercetin, Myricetin, Isorhamnetin, Läke-
medelsinteraktioner, FDI 
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Abbreviations 
 
CYP450 Cytochrome P450 
FDI Food-drug interactions 
ADE Adverse drug event 
NADPH β-nicotinamide adenine dinucleotide phosphate 
PNP p-nitrophenol 
BR Benzyloxyresorufin 
BFC 7-benzyloxy-4-trifluoromethylcoumarin 
HFC 7-hydroxy-7-benzyloxy-triflouromethylcoumarine 
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1.1 Background 
Cytochrome P450 enzymes (CYP450s) are the main group of enzymes responsible for the 
metabolism and detoxification of foreign substances, commonly called xenobiotics. They are 
also involved in the biosynthesis and metabolism of endogenous compounds such as fatty ac-
ids and steroids. CYP450s are highly expressed in the liver, where they catalyse reactions that 
convert lipophilic compounds into more hydrophilic derivatives. Most drugs undergo this bio-
transformation in order to be catabolised and eliminated from the body (Gonzalez, 1988). 
However, other xenobiotic compounds such as dietary flavonoids can modulate the activity of 
CYP450 enzymes leading to an enhancement or inhibition of the catalytic activity. Conse-
quently, the detoxification or functionality of drugs may be interrupted (Hodek et al., 2002).  
In the present study, the flavonoids quercetin, myricetin and isorhamnetin were examined 
for their inhibitory effects on enzyme activity of two CYP450 isoforms. These flavonoids are 
naturally occurring in a wide range of vegetables in the human diet and known to interact with 
several CYP450 enzymes (Chen et al., 2009; Guo and Zheng, 2014; Lau and Chang, 2009). 
Emerging in vitro and in vivo evidence propose health effects of many flavonoids attributable 
to their anti-oxidative properties (C.f. Bodewes et al., 2011). Accordingly, supplements con-
taining high concentrations of flavonoids are commonly consumed to prevent health issues. 
However, knowledge about the underlying mechanisms are limited. (Hollman, Cassidy et al. 
2011). Moreover, when co-administrated with prescription drugs there is a considerable risk 
for adverse health effect since knowledge about potential food-drug interactions (FDI) is still 
scarce. Understanding the mechanisms behind FDI with CYP450 enzymes can improve the 
development of new medicines for animals and humans and minimize the risk for adverse ef-
fects of drugs (Wanwimolruk and Prachayasittikul, 2014). 
Besides diet and other lifestyle factors, the expression and activity of CYP450 enzymes 
depend on genetic profile, age and gender (Zanger and Schwab, 2013). These inter-individual 
variations in enzyme activity make it difficult to predict individual drug response. The effect 
of dietary components on CYP450 activity may also vary between men and women. Gender 
related differences in the effect of phytochemicals on CYP450 activity has previously been 
reported in porcine microsomes (Ekstrand et al., 2015) but very few studies have investigated 
this phenomenon in humans. Therefore, this study on gender related differences in CYP activ-
ity in human microsomes provides new and important knowledge about CYP450 regulation in 
humans.  
1 Introduction 
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1.2 Objectives 
The aim of the present study was to evaluate gender-related inhibitory effects of selected die-
tary flavonoids on hepatic CYP450 activity in human males and females in vitro. A secondary 
goal was to examine the mode of enzyme inhibition. 
Specifically, quercetin was investigated for its inhibitory effect on CYP2E1 activity and 
quercetin, myricetin and isorhamnetin were investigated for their inhibitory effects on 
CYP3A4 activity. The choice of flavonoids and CYP450 isoforms was based on a recently 
published study which demonstrated that quercetin inhibited CYP2E1, and querctietin, myri-
cetin and isorhamnetin inhibited CYP3A4 in a gender-related manner in pigs (Ekstrand et al., 
2015).  
Given that pigs and humans have a lot of physiological similarities, the hypothesis of this 
study was that in the presence of the selected flavonoids, human CYP2E1 and CYP3A4 activ-
ity would be inhibited in a gender dependent manner.  
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With regards to the objectives of this study, the following paragraphs give an overview of the 
role of CYP450 enzymes in human metabolism with special emphasis on xenobiotic metabo-
lism. Relevant information about mechanisms in CYP450 regulation is reviewed. Further-
more, the current knowledge status of food-drug interactions involving CYP2E1 and CYP3A4 
and the selected flavonoids are presented. 
2.1 The Cytochrome P450 system 
Cytochrome P450 enzymes evolved in early organisms over 1.4 billion years ago as a system 
to cope with foreign substances. Environmental changes such as when vertebrates moved 
from the sea to land lead to increased exposure to new substances and contributed to the de-
velopment of the CYP450 system and to a wide diversity of the enzymes (Gonzalez, 1988).  
The research of CYP450 enzymes stretches back to the 1950’s when Klingenberg, (1958) 
discovered a pigment with the maximum absorption of 450 nm when bound to carbon monox-
ide. A decade later it  was further characterized as a heme protein that catalyses reactions in 
the cytochrome P450 monooxygenase system (Harding et al., 1964; Omura and Sato, 1962). 
In animal species CYP450s are present at two different locations within the cell. Microso-
mal CYP450s are located in the endoplasmic reticulum. They are mainly involved in xenobi-
otic metabolism particularly in the liver. Mitochondrial CYP450s function in the biosynthesis 
of steroids also in extrahepatic tissues (Omura, 2010).  
 
2.1.1 Reaction model 
Most CYP450-mediated reactions involve insertion of a single oxygen atom derived from mo-
lecular oxygen into an organic molecule. Such reaction is classified as for example hydroxyla-
tion, sulfoxidation, epoxidation, N-dealkylation or O-dealkylation depending on the substrate 
to be converted. The general catalytic cycle starts when a substrate, typically hydrophobic, 
binds to the active site of the CYP450 enzyme forming an enzyme-substrate complex. The cy-
cle continues with a series of reactions that require the enzyme cytochrome P450 reductase to 
generate a supply of electrons from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). The enzyme-substrate complex attracts dioxygen to the reduced heme group (Fe2+) 
at the enzyme. In the end of the cycle, water and a hydroxylated, more hydrophilic product, 
dissociates from the enzyme complex (Ortiz de Montellano and Voss, 2005). A simplified 
paradigm of the overall reaction is presented in Figure 1. In reality the system is far more 
2 Literature review  
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complex and dynamic. It is thought that oxygenated intermediates can be released at any step 
in the cycle, potentially generating reactive oxygen species (ROS) and the reactions do not 
necessarily proceed in order (Krest et al., 2013).  
 
 
 
 
 
2.1.2 CYP450 isoforms 
More than 15 000 CYP450 genes coding for varieties of the enzymes have been identified 
across all biological kingdoms. They are divided into gene families, subfamilies and finally 
individual genes based on their amino acid sequence profile. Humans possess only 57 active 
CYP450 genes (compared to 102 in mouse) grouped into 18 families and 44 subfamilies (Nel-
son et al., 2004). CYP450 family 1-3 are mainly involved in detoxification of exogenous 
compounds and the remaining CYP450 families regulate metabolism of endogenous com-
pounds such as fatty acids and steroids (Ingelman-Sundberg and Sim, 2010).    
   The nomenclature of the enzymes is structured as follows: CYP450 followed by a number 
for family, a letter for subfamily and a number for the isoenzyme. For example, CYP2E1 and 
CYP3A4 investigated in this study represent different families. The expression of CYP450 
enzymes varies widely between species, age, gender, homeostasis of the organism and is often 
tissue specific. Although expressed in almost all organs, human CYP450s are especially con-
centrated in the liver where CYP3A4 accounts for the largest fraction (30%), followed by 
CYP2C (20%), CYP1A2 (13%), CYP2E1 (7%), CYP2A6 (4%), CYP2D6 (1-5%) and 
CYP2A6 (<1%) (Shimada et al., 1994).   
 
2.2 CYP450 in xenobiotic metabolism 
Biotransformation of foreign compounds is an important function of CYP450 enzymes since a 
disruption of enzyme activity may produce toxicity that is detrimental for the health of the or-
ganism. The metabolic process comprises three steps: Phase I modification, Phase II conjuga-
tion and Phase III transport (Hoffmann et al., 2014). Microsomal CYP450 enzymes operate in 
the first phase by introducing polar groups to the foreign substance (Guengerich, 2001).  
Most xenobiotics are metabolised by only a dozen human CYP450s belonging to CYP450 
families 1-3. The most relevant enzymes involved in drug metabolism are six CYP450 
isoforms that metabolise as much as 90 % of all prescribed drugs. The complex regulation of 
CYP450 activity makes it difficult to predict the fate of drugs and possible adverse drug 
events (ADE). Therefore, the drug industry is particularly interested in the research of 
CYP450 regulation (Lynch and Price, 2007; Zanger and Schwab, 2013).  
The most common and well-studied mechanism underlying FDIs is inhibition of drug me-
tabolising enzymes (Wienkers and Heath, 2005). In addition to inhibition of enzymes, drug 
 
Figure 1. Cytochrome P450 catalysis. RH represents any substrate that binds to the enzyme’s heme group 
(Fe3+) at the active site. ROH represents the final hydroxylated and more hydrophilic product.  
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transporters are susceptible to inhibition and can thus influence drug metabolism (Arnaud et 
al., 2010). Furthermore, increased expression of enzymes or transporters may modulate xeno-
biotic metabolism, often via receptor-mediated gene transcription (Hewitt et al., 2007). The 
present study is exclusively devoted to direct enzyme inhibition.  
 
2.2.1 Enzyme inhibition 
Any substance, including many drugs and dietary components, that reduce the velocity of en-
zymatic reactions are called inhibitors. There are two distinct types of inhibition, namely re-
versible and irreversible inhibition as described by Mathews et al., (2012);  
 
 Reversible inhibition is called so because of the weak binding between the inhibitor and 
the enzyme that easily dissociates and reverses the inhibition. The binding action depends 
on the molecular structure of the enzyme and the inhibitor that further distinguish differ-
ent modes of reversible inhibition:   
 
– Competitive inhibitors compete with the substrate for binding to the active site of 
the enzyme. As a result, the proportion of bound substrate diminishes and the cat-
alytic activity decreases. The inhibition can be avoided by increasing the substrate 
concentration.  
– Uncompetitive inhibitors bind only to the enzyme-substrate complex. Since the 
inhibitor and substrate bind to different sites they do not structurally resemble 
each other. Upon binding, a conformational change distorts the catalytic reaction 
that cannot be overcome by increased substrate concentration. 
– Mixed inhibitors bind either to free enzyme or to the enzyme-substrate complex 
also at a site distinct from the active site. A slight conformational change in the 
enzyme complex makes the substrate binding to the active site not optimal and 
hence, reduces the enzyme activity. Inhibition cannot be overcome by increased 
substrate concentration because the inhibitor and the substrate do not compete for 
the same site.    
– Non-competitive inhibition is a special case of mixed inhibition where the inhibi-
tor has the same binding affinity to the free enzyme and the enzyme-substrate 
complex.  
 
 Irreversible inhibition, also called mechanism-based inactivation, occurs when the inhibi-
tor constructs strong, covalent bonds with the enzyme that are unlikely to break. It alters 
the structure of the enzyme so that the inhibition cannot be reversed.  
 
 
In practice, reversibility is often studied in vitro by including a pre-incubation step prior to ad-
dition of the probe substrate. In case of irreversible inhibition, the degree of inhibition in-
creases after inclusion of a pre-incubation step. In contrast, reversible inhibition is unaffected 
by pre-incubation due to the inhibitor’s ability to rapidly dissociate from the enzyme 
(Mathews et al., 2012). The type of reversible inhibition can be further examined with help of 
a kinetics study explained in the next paragraph.  
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2.2.2 Michaelis Menten kinetics  
In biochemistry, the Michaelis-Menten equation is the most applicable approach for describ-
ing enzymatic reactions (Figure 2.). It is an essential tool when studying reversible CYP450 
inhibition. The equation describes the reaction velocity as a function of substrate concentra-
tion that appears as a hyperbolic curve when viewed in a diagram (Figure 3). Vmax reflects the 
maximum reaction velocity in which the enzyme is saturated with substrate. The Michaelis 
constant (Km) is the substrate concentration needed to achieve half of Vmax and reflects the 
binding affinity of the substrate to the enzyme. A high Km indicates low binding affinity and 
more substrate is required to achieve half of Vmax.  
 
 
 
𝑉 =
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +  [𝑆]
 
 
 
Figure 2. The Michaelis Menten equation 
 
 
 
 
 
 
 
Figure 3. Michaelis Menten plot describing the reaction velocity, V, as a function of substrate concen-
tration, yielding Km and Vmax. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: 
W H Freeman; 2002. Section 8.4, The Michaelis-Menten Model Accounts for the Kinetic Properties of 
Many Enzymes. Available at: http://www.ncbi.nlm.nih.gov/books/NBK22430/ [2016-04-20] 
 
 
 
In vitro studies of CYP450 inhibition use a range of combined substrate and inhibitor concen-
trations in order to investigate the mode of inhibition. The results viewed in a Michaelis-Men-
ten plot (Figure 3) are interpreted as described by Berg et al., (2002): 
 
- Competitive inhibition yields a high Km but does not affect Vmax since inhibition is over-
come by higher substrate concentration. 
- In uncompetitive inhibition, both Km and Vmax are reduced because the inhibitor increases 
the effective substrate binding but inhibit the catalytic process. 
- In the case of mixed inhibition, Km increases and Vmax decreases because the binding of the 
inhibitor affect the substrate binding and vice versa.  
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- Non-competitive inhibition is characterized by an unchanged Km value and decreased Vmax 
due to the unaffected substrate binding and impaired enzyme functionality. 
 
 
The half maximum inhibitory concentration (IC50) and inhibition constant (Ki) are both terms 
that describe how effective the inhibitor is and are frequently used when evaluating the po-
tency of drug candidates. More specifically, IC50 is the concentration of an inhibitor that 
causes 50 % inhibition of the CYP450 enzyme activity and Ki, also called the dissociation 
constant, is a kinetic measure that reflects the strength of interaction between the enzyme and 
the inhibitor. The Ki value for an inhibitor is interpreted analogous with the Km for a substrate, 
i.e. a low Ki indicates a strong binding affinity of the inhibitor to the enzyme and a high Ki in-
dicates weak binding capacity. Its formula depends on the mode of inhibition. In the case of 
non-competitive inhibition, the Ki value is equal to IC50. During competitive and uncompeti-
tive inhibition, Ki is considered to be half of IC50. For mixed inhibition, the Ki value ranges 
from IC50 to IC50/2 (Haupt et al., 2015). Whereas the IC50 value depends on enzyme-, inhibi-
tor- and substrate concentrations as well as other experimental conditions, the Ki value is in-
dependent of the substrate concentration but depends on the enzyme and inhibitor (Cer et al., 
2009).  
2.3 Food-drug interactions involving CYP450 
Many plant derived food components have the ability to interfere with CYP450 mediated 
drug metabolism that may cause FDI. The most recognised examples are studies of grape fruit 
juice and St. John’s wort which have shown clinically significant interactions with the metab-
olism of prescribed drugs. Other in vitro and in vivo studies have indicated interactions be-
tween extracts of fruit, berries and herbs with several CYP450 enzymes (Wanwimolruk and 
Prachayasittikul, 2014). For example, extracts from blueberry, ginkgo biloba and garlic, in-
cluding their bioactive components, have been studied for their potential role in food-drug in-
teractions. The interaction often leads to a change in bioavailability of the drug, sometimes 
beneficial for the patient, in other cases it causes adverse or even dangerously toxic effects 
(Wanwimolruk and Prachayasittikul, 2014). The grade of interaction depends on the charac-
teristics of the drug and active food constituents, the involved CYP450 enzymes, dosage, and 
health status of the patient. Supplements containing high levels of interacting components are 
available at the market and claimed to be beneficial for health. From a clinical perspective, 
the fact that supplements are not uncommonly taken concomitantly with drugs is of special 
concern (Wanwimolruk and Prachayasittikul, 2014).  
 
2.4 Inhibition by dietary flavonoids 
Flavonoids constitute a large group of plant pigments present in vegetables, fruits, berries and 
herbs that are consumed by most people on a daily basis. They have been extensively studied 
for their bioactive properties in vitro and in vivo. The anti-oxidative properties of flavonoids 
explain the apparent anti-carcinogenic activities where CYP450 enzymes is highly involved 
in the mechanism of action (Kale et al., 2008). Flavonoids can interact with CYP450 enzymes 
by modulating (inhibition or induction) biosynthesis of the enzymes or the catalytic activity. It 
may occur at a transcriptional or gene translational level as well as direct modulation of 
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CYP450 activity (Hodek et al., 2002). Flavonoids possessing a hydroxyl group generally in-
hibit CYP450 enzymes whereas flavonoids lacking hydroxyl groups may induce CYP450-de-
pendent activities (Buening et al., 1981).  
In nature, flavonoids occur mostly as glycosides where one of the hydroxyl groups is re-
placed by a sugar molecule such as glucose, rhamnose or rutinose. Sugar attached flavonoids 
have increased water solubility and are considered non-absorbable in the gut. Nevertheless, 
colon bacteria hydrolyses them into more lipophilic free flavonoids (aglycones) that are able 
to pass the intestinal border by simple diffusion (Hodek et al., 2002). In general, the flavonoid 
content in dietary plants is more concentrated in the seeds and outer part of the plant. Grow-
ing conditions and thermal processing as well as the extraction method are factors that influ-
ence the flavonoid contents measured in food (Harris et al., 2015; Mitchell et al., 2007; Wach 
et al., 2007). Hollman and Katan (1999) reported an average daily flavonoid intake of 
23mg/day in the Netherlands where quercetin and myricetin were included in the observation, 
but stressed that it varies widely depending on the diet. 
Quercetin, myricetin and isorhamnetin (Figure 4) are all members of the flavonol sub-
group of flavonoids. Major food sources include onions, apples, kale, broccoli, apples, cher-
ries, berries tea and red wine (Moon et al., 2006). Flavonols and other groups of flavonoids 
are bioactive constituents in many herbal extracts that are known to modulate CYP450 activ-
ity. Gingko Biloba for instance is used in alternative medicine to treat cerebrovascular dis-
eases and memory impairment where quercetin, myricetin and isorhamnetin among other fla-
vonoids are considered to be the responsible mediators (Cho and Yoon, 2015; Lau and Chang, 
2009). A three-ring molecule with hydroxyl (OH-) groups attached make up the backbone of 
flavonols. Their similar structure means that they share some similarities in properties. The 
number of hydroxyl groups seems to correlate to the degree of inhibition. Myricetin and quer-
cetin have showed stronger inhibition than flavonoids with less hydroxyl groups, and myrice-
tin having one more hydroxyl group than quercetin was the more potent in vitro inhibitor of 
CYP2E1 and CYP3A4 activity (Ho et al., 2001; Li et al., 1994).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4. Chemical structure of the flavonoid aglycones of quercetin, myricetin and isorham-
netin. 
Structures were retrieved from Mitchell et al., (2007) (Quercetin), Ong and Khoo, (1997) (Myri-
cetin) and Wikipedia (2009). Isorhamnetin. https://upload.wikimedia.org/wikipedia/com-
mons/5/54/3-methylquercetin.svg [2016-04-20] (Isorhamnetin) 
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2.4.1 Quercetin 
Quercetin is the most abundant flavonoid in the human diet and hence also the most studied. 
It is distributed in a wide range of vegetables and consumed daily by most people worldwide. 
A review from the U.S. Department of Agriculture lists raw capers as the richest food source 
of quercetin (234mg/100g of the edible portion), followed by lovage (170mg/100g) (Bhagwat 
et al., 2014). In the western world, apples, onions and red wine account for the largest share of 
quercetin consumption although they contain much less quantities per 100g (Rodgers and 
Grant, 1998). Absorption of quercetin in the intestines is accompanied by methylation, sulfat-
ination and glucuronidation, yielding many metabolites that are further metabolised in liver 
and kindeys. Twenty-one quercetin related compounds have been found in human urine 
(Kelly, 2011).                      
Quercetin inhibit several CYP isoforms including CYP1A2 and CYP2E1 in vitro and 
CYP3A4 both in vitro and in vivo (Moon et al., 2006). A number of clinical studies indicate 
positive health effects of quercetin, for example blood pressure lowering effects. In most 
other areas such as cancer prevention the research is still limited to in vitro experiments 
(Kelly, 2011).    
 
2.4.2 Myricetin 
Various species of berries contain relatively high contents of myricetin as well as fennel and 
parsley leaves although carob is the richest dietary source (Bhagwat et al., 2014). Myricetin is 
structurally similar to quercetin and therefore have similar functions. Generally, it is present 
in the same vegetables, but to a much lesser extent than quercetin (Bhagwat et al., 2014; Ong 
and Khoo, 1997).  
Research on myricetin is often devoted towards its protective role in metabolic and cancer 
diseases whereas studies on specific CYP450 inhibition by myricetin are less common. How-
ever, Ekstrand et al., (2015) demonstrated that myricetin competitively inhibit CYP1A activ-
ity and non-competitively inhibit CYP3A in porcine liver microsomes. Studies of rat liver mi-
crosomes have found myricetin to be an inhibitor of CYP3A, CYP2C9 (Choi et al., 2010) and 
a stronger inhibitor of CYP1A2 than quercetin (Li et al., 1994). Furthermore, it exhibited 
mixed-type inhibition of CYP2A6 in human liver microsomes (Tiong et al., 2010).  
 
2.4.3 Isorhamnetin 
Isorhamnetin is a metabolite of quercetin and also occurs naturally in vegetables. Most vege-
tables included in the report from U.S. Department of Agriculture contain only traces or no 
isorhamnetin. Nevertheless, parsley, kale and sea buckthorn contain amounts comparable to 
quercetin (Bhagwat et al., 2014). In consort with quercetin and myricetin, isorhamnetin has 
demonstrated cytoprotective and antioxidative capacity along with anti-adiposigenesis and 
anti-inflammatory effects (Si et al., 2012).  
Isorhamnetin has been found to inhibit hepatic porcine CYP1A and CYP3A activity in a 
competitive manner (Ekstrand et al., 2015). Furthermore, hepatic CYP2B6 activity was inhib-
ited in vitro by isorhamnetin aglycone in contrast to the glyosidic counterpart which did not 
exhibit inhibition (Lau and Chang, 2009).  
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A compilation of CYP450 enzymes inhibited by quercetin, myricetin and isorhamnetin re-
spectively is presented in Table 1. 
 
 
 
Table 1. Overview of previously investigated inhibitory effects on CYP450 activity by quercetin, myri-
cetin and isorhamnetin  
CYP450 
isoform 
Flavonoid Model Effect Reference 
CYP1A1 
Quercetin Recombinant  Inhibition 
Schwarz et al., 2011 
 
Myricetin Recombinant  Inhibition 
Isorhamnetin Recombinant Inhibition  Takemura et al., 2010 
CYP1A2 
Quercetin HLM  
Non-competitive inhibi-
tion  
Rastogi and Jana, 
2014 
Quercetin Recombinant Inhibition  
Takemura et al., 2010 
Isorhamnetin Recombinant Inhibition 
CYP1B1 
Quercetin Recombinant  Inhibition  
Takemura et al., 2010 
Isorhamnetin Recombinant Inhibition  
CYP2A6 
Quercetin HLM Competitive inhibition 
Tiong et al., 2010 
 
Myricetin HLM Mixed type inhibition 
CYP2B6 
Quercetin HLM  Inhibition  
Lau and Chang, 2009 
 
Isorhamnetin HLM Inhibition 
CYP2C8 Quercetin Recombinant Irreversible inhibition Pang et al., 2012 
CYP2C9 Quercetin HLM  Competitive inhibition  
Rastogi and Jana, 
2014 
 
CYP2C19 Quercetin HLM  Competitive inhibition  
CYP2D6 
Quercetin HLM  Competitive inhibition  
Quercetin  LM male rats Inhibition 
Vijayakumar et al., 
2015 
CYP2E1 Quercetin 
Male porcine 
LM 
Competitive inhibition 
Ekstrand et al., 2015 
 
CYP3A 
Myricetin 
Male porcine 
LM 
Non-competitive inhibi-
tion 
Isorhamnetin 
Male & female 
porcine LM 
Competitive inhibition 
CYP3A4 
Quercetin HLM and HIM Inhibition  Fasinu et al., 2013 
Myricetin Recombinant Inhibition  Choi et al., 2010 
HLM = human liver microsomes, LM = liver microsomes, HIM = human intestinal microsomes  
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2.5 Cytochrome 2E1  
The isoform CYP2E1 is expressed in various organs and tissues and is one of the major he-
patic CYP450 enzymes in humans. It metabolises relatively small hydrophobic endogenous 
and exogenous compounds including several steroids as well as drugs such as chlorozoxazone 
and paracetamol. Chlorozoxazone is frequently used as a probe substrate since CYP2E1 ex-
hibits high specificity for the compound. The present study used another specific substrate, P-
Nitrophenol (PNP). It rapidly metabolises to nitrocatechol and is therefore suitable for in vitro 
assays (Cederbaum, 2014).  
Research on CYP2E1 regulation is mostly focused on its association with various cancers 
since the enzyme is an efficient activator of chemical carcinogenesis (Zanger and Schwab, 
2013). Induction of CYP2E1 is linked to several types of cancer caused by the generation of 
reactive oxygen species (ROS) that cause cell damage. The enzyme is inducible by many of 
its own substrates and several hormones at a transcriptional, translational and posttranslational 
level (Gonzalez, 2007). Ethanol is an example of an inducing CYP2E1 substrate that is a 
causative player in alcoholic and non-alcoholic liver disease caused by ROS production (Au-
bert et al., 2011). Moreover, CYP2E1 expression is elevated during several other physiologi-
cal conditions including diabetes, obesity, fasting and smoking (Caro and Cederbaum, 2004; 
Girre et al., 1994).  
Numerous phytochemicals are considered anti-carcinogenic attributable to their ability to 
inhibit CYP2E1 (Barcelo et al., 1996; Wargovich, 2006). Furthermore, CYP2E1 inhibitors 
such as the irreversible inhibitor disulfiram are utilized in clinical practises against alcohol 
abuse (Pelkonen et al., 2008). The antioxidant disulfiram, diethyldithio-carbamate and the ac-
tive constituent in garlic, diallylsulfide, are known irreversible inhibitors of CYP2E1 (Cho 
and Yoon, 2015). The proclaimed health beneficial ingredient in red wine, resveratrol, is a 
non-competitive CYP2E1 inhibitor (Piver et al., 2001). Additional phytochemicals present in 
various food products and herbs have indicated inhibitory effects including licochalcone from 
liquorice (He et al., 2015), isoflavones from soy (Fan et al., 2013), black tea catechins (Catter-
all et al., 2003), black pepper (Kang et al., 1994) and ginseng (Kim et al., 1997). Most studies 
were conducted in the liver or intestine of mice and rats and the results can therefore not ap-
ply to humans. Zuber et al., (2002) pointed out that although active components from milk 
thistle inhibited CYP2E1 in human liver microsomes, the plasma concentrations of those 
compounds following dietary uptake do not reach the concentration required for inhibition. 
Therefore, CYP2E1 inhibition by milk thistle in the diet is unlikely.    
2.6 Cytochrome 3A4 
CYP3A4 is the most abundant CYP450 enzyme in the liver and the main metabolising en-
zyme of approximately 50% of all prescribed drugs (Pelkonen et al., 2008). The small intes-
tine also hosts significant CYP3A4 content where it substantially contributes to phase I me-
tabolism of xenobiotics (von Richter et al., 2004). It is involved in bioactivation of procarcin-
ogens such as aflatoxin (Gonzalez and Gelboin, 1994). Furthermore, several clinical studies 
have reported FDI involving irreversible inhibition of CYP3A4 activity. Orally administrated 
drugs were insufficiently degraded and accumulating in its active form in the blood circula-
tion, sometimes causing unfavorable toxicity (Zhou et al., 2007; Chen et al., 2012).  
The diverse functions of CYP3A4 can be attributed to its chemical structure. It exhibits a 
broad substrate preference due to its large and flexible active site that allows large or multiple 
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small molecules to bind. Substrates include several clinical drugs such as immunosuppres-
sants, antibiotics and statins along with endogenous steroids such as testosterone, progester-
one and bile acid (Zanger and Schwab, 2013). A recommended probe substrate for CYP3A4 
inhibition assays is 7-benzyloxy-4-trifluoromethylcoumarin (BFC) which was used in this 
study. Although BFC is metabolised by several CYP450 isoforms, dealkylation to hydroxy-4-
trifluoromethylcoumarin (HFC) by CYP3A4 is especially sensitive to inhibition (Renwick et 
al., 2000; Stresser et al., 2000).  
Consistent with low substrate selectivity, CYP3A4 is susceptible to inhibition by a broad 
variety of substances. Known inhibitors are structurally divergent, ranging from antifungal 
agents, antimicrobial and antihypertensives to herbal and food constituents (Pelkonen et al., 
2008). Grapefruit juice is a well recognised CYP3A4 inhibitor and responsible for several 
clinically relevant FDI proved in clinical studies (Ameer and Weintraub, 1997). The juice is 
rich in flavonoids that individually also have inhibitory effects, for example naringin (Vero-
nese et al., 2003). Resveratrol is a bioactive component of red wine, this flavonoid has been 
shown to interact with drug metabolism in human volunteers (Chow et al., 2010). 
Research of CYP3A4 inhibition has revealed a few contradictory findings. The anti-de-
pressive herb St. John’s wort for instance inhibited CYP3A4 in vitro (Obach, 2000) but pro-
longed exposure increased CYP3A4 expression (Lau et al., 2011). A possible explanation 
proposed by Xie and Kim (2005) is that multiple inhibitors and inducers in the herb influence 
the enzyme expression in a feedback fashion. Gurley et al., (2005) showed that St. John’s 
wort strongly induced CYP3A4 expression and to a less extent CYP2E1 in elderly subjects 
and discouraged concomitant ingestion of herbal supplements with prescription drugs to avoid 
herb-drug interactions.   
Quercetin is one of the major phytochemicals in St. John’s wort and has also showed con-
tradictory effects on CYP3A4 activity. It inhibited felodipine metabolism in human liver mi-
crosomes (Fasinu et al., 2013) but in vivo studies of rats have showed conflicting results 
where both inhibition (Choi et al., 2011) and induction have been detected. The glucoruni-
dated metabolites of quercetin following oral administration was thought to cause the enzyme 
activation (Yu et al., 2011).  
Similar to CYP2E1 inhibition, CYP3A4 was inhibited by licochalcone, black pepper and 
irreversibly by resveratrol (Piver et al., 2001). Tiliroside is a flavonoid present in several 
berry species such as raspberries and is a strong CYP3A4 inhibitor (Sun et al., 2010). Like-
wise, Gingko Biloba inhibited CYP3A4 activity through inhibition of BFC metabolism in hu-
man microsomes (Gaudineau et al., 2004).  
 
There are many more inhibitors of CYP2E1 and CYP3A4 metabolism than the above men-
tioned examples. This literature review presented the most relevant and investigated inhibitors 
deriving from dietary sources.    
 
2.7 Gender related differences in CYP450 activity 
Since CYP450 genes are located on autosomal chromosomes, gender differences in gene ex-
pression are not expected. Observed variations in expression and activity can therefore be at-
tributed to endogenous hormonal influences (Meibohm et al., 2002). However, Penaloza et 
al., (2014) asserted that inborn differences between male and female CYP450 expression do 
exist through different methylation patterns in the embryo that persist in primary cells. They 
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found certain methylation patterns associated with higher expression of CYP1A1, CYP2E1 
and CYP7B1 in tissues and cell cultures of female mice compared to male.  
Human studies on gender differences in CYP450 regulation is often studied by quantifying 
the metabolism of probe substrates for specific CYP450 isoforms. Epidemiological studies 
with clinical drugs have reported 24-40 % higher CYP3A activity in women (Kahan et al., 
1986; Krecic-Shepard et al., 2000; Lew et al., 1993; Meibohm et al., 2002).  However, other 
studies suggested that the higher CYP3A metabolism is due to lower expression of the drug 
transporter P-glycoprotein in women  (Kinirons et al., 1999; Lan et al., 2000; Meibohm et al., 
2002). Furthermore, in vitro studies could not detect gender differences in CYP3A activity in 
human liver microsomes (Schmucker et al., 1990; Shimada et al., 1994).  
Several studies have reported higher activity of CYP1A2 in men compared to women, 
(Bartoli et al., 1996), (Bock et al., 1994; Ou-Yang et al., 2000; Relling et al., 1992). Men also 
expressed higher CYP2E1 activity indicated by faster oral clearance of the probe substrate 
chlorzoxazone than women. However, the difference was less pronounced after normalisation 
for body weight, indicating bodyweight-related disparities rather than gender-related (Kim 
and O’Shea, 1995). A number of human studies have reported significantly higher CYP2D6 
activity in women than in men, these findings are of clinical importance since the isoform is 
an exclusive metaboliser of several therapeutic agents (Hägg et al., 2001; Labbe et al., 2000; 
Tamminga et al., 1999).  
Despite its clinical relevance, gender related differences in CYP450 regulation only re-
cently attracted researcher’s attention. The influence of dietary components such as flavo-
noids on CYP450 regulation may be gender-dependent but is not well studied. Ekstrand et al., 
(2015) found that myricetin, isorhamnetin and quercetin affected porcine CYP1A, CYP3A 
and CYP2E1 activity and the mode of inhibition in a gender-dependent manner. Thus, study-
ing this phenomenon in humans is a unique addition to the research of CYP450 regulation.  
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An in vitro experiment was set up to analyse gender related differences in degree of enzyme 
inhibition and the type of inhibition.  
CYP2E1activity was measured using the probe substrate PNP and CYP3A4 activity was 
measured using BFC as probe substrate. Well established HPLC methods were used to quan-
tify 4-nitrocatechol, product of PNP metabolism, and 7-hydroxy-4-trifluoromethylcoumarin 
(HFC), product of BFC metabolism. The procedure consisted of mixing and incubating inhib-
itor (quercetin, myricetin, isohamnetin), enzyme, substrate, electron donor (NADPH) and 
buffer in test tubes followed by measuring product formation.  
Substrate specificity and enzyme inhibition in the presence of an inhibitor were examined 
by using human recombinant enzymes expressed in Saccharomyces cerevisiae. The same en-
zyme was used to test if the catalytic activity followed a Michaelis-Menten curve.  
The following step was to carry out the same experiment in female and male human liver 
microsomes. Two female and two male pools were analysed, each pool containing samples 
from approximately 20 individuals. If inhibition occurred, enzyme reversibility was tested 
through inclusion of a pre-incubation step. In case of reversible inhibition, multiple substrate 
concentrations were investigated to achieve the maximum velocity (Vmax) of the enzyme ac-
tivity, the Michaelis-Menten constant (Km) and the inhibition constant (Ki) in order to deter-
mine the mode and strength of inhibition. Inhibition was defined as a 50 % or more decrease 
in catalytic activity in at least one sample within enzyme pools. The decrease was in compari-
son to the control which was set to have 100 % catalytic activity.    
An overview of the experimental design is shown in Figure 5. 
 
 
 
 
 
 
 
 
 
 
3 Material and method
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3.1 Chemicals 
Quercetin dehydrate 98%, 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-hydroxy-7-ben-
zyloxy-triflouromethylcoumarine (HFC), 7-benzyloxyresoruﬁn (BR), reduced β-nicotinamide 
adenine dinucleotide phosphate (NADPH) were purchased from Sigma-Aldrich (Steinheim, 
Germany). Isorhamnetin and myricetin were purchased from Fluka (Buchs, Switzerland). 
HPLC grade acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). 
Quercetin, isorhamnetin and myricetin were dissolved in methanol, BFC in dimethyl sulfox-
ide and HFC and NADPH in 0.05 M potassium phosphate buffer (pH 7.4). All stock solutions 
were stored at −80 °C, and working solutions at −20 °C. 
 
3.2 Microsomes  
CYP2E1 and CYP3A4 human recombinants, expressed in Saccharomyces cerevisiae and mi-
crosomes from liver, pooled separately from human female and male were purchased from 
Sigma-Aldrich (Steinheim, Germany). Additionally, human liver microsomes pooled from 20 
female individual donors and 20 male individual donors were purchased from Life technolo-
gies Europe BV (Netherlands). Protein concentration in all human liver microsomes was 20 
mg/ml. 
3.3 Analysis of CYP2E1  
Hydroxylation of PNP to p-nitrocatechol was measured to determine the catalytic activity of 
CYP2E1 (Tassaneeyakul et al., 1993). Incubations contained 10 pmol of human recombinant 
cDNA-expressed CYP2E1 or 0.2 mg of human liver microsomal protein, 0.2 mM of PNP and 
1.0 mM NADPH in incubation buffer (0.1 M potassium phosphate, pH 6.8) and 2µl of 16, 32 
or 128 µl inhibitor or methanol (control). For the kinetic measurements, samples with 16 µl 
Figure 5. Overview of the experimental design.  
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inhibitor were not prepared. The final incubation volume was 0.25 ml. Incubation was per-
formed in a water bath at 37 °C, for 30 min. The reaction was terminated with 0.02 ml of 40% 
trichloroacetic acid. The tubes were vortexed and centrifuged at 10000g for 5 min. Superna-
tants were transferred to HPLC vials and concentrations of p-nitrocatechol were measured us-
ing the HPLC system consisting of a pumping system (L-7100), autosampler (AS 7200), fluo-
rescence detector (L-7485), UV detector (L-7400) set at 345 nm, and D-7000 HPLC Manager 
software (Merck, Hitachi, Tokyo, Japan). Hypersil ODS column (5 μm, 60 × 4.6 mm, 
Hewlett–Packard, Palo Alto, CA, USA) equipped with a guard column was used. P-nitrocate-
chol was eluted using an isocratic mobile phase consisting of 0.1% trifluoroacetic acid in 25% 
acetonotrile at a flow rate of 1.0 ml/min. PNP hydroxylation was also investigated in human 
recombinant CYP3A4 according to the same procedure.  
 
3.4 Analysis of CYP3A4 
Metabolism of BFC to HFC was measured to determine the activity of CYP3A (Renwick et 
al., 2000). Incubations contained 5 pmol of human recombinant cDNA-expressed CYP3A4 or 
0.05 mg of human liver microsomal protein, 25 µM of BFC and 1.0 mM NADPH in incuba-
tion buffer (50 mM potassium phosphate, pH 7.4) and 2µl of 16, 32 or 128 µl inhibitor or 
methanol (control). For the kinetic measurements, samples with 16 µl inhibitor were not pre-
pared. The final incubation volume was 0.5 ml. Incubation was performed in a water bath at 
37 °C, for 10 min. The reaction was terminated with 0.5 ml of ice cold methanol. The tubes 
were vortexed and centrifuged at 10000g for 5 min. Supernatants were transferred to HPLC 
vials and concentrations of HFC were measured using the same HPLC system as for 
CYP2E1, except for the detector. HFC was eluted using an isocratic mobile phase of 50 mM 
phosphate buffer:methanol:acetonitrile (52:45:3, v/v) at a flow rate of 1.0 ml/min and de-
tected with a fluorescence detector (410 and 538 nm for excitation and emission wave-
lengths). In addition to O-dealkylation by BFC, O-dealkylation of the substrate ben-
zyloxyresorufin (BR) was investigated in human recombinant CYP3A4.  
 
3.5 Data analysis 
Enzyme kinetic and inhibition parameters were estimated using GraphPad Prism 4.0 
(GraphPad software Inc., CA, USA). Michaelis constant (Km), maximal velocity (Vmax) and 
dissociation constant for inhibitor binding (Ki) values were obtained from Michaelis–Menten 
non-linear regression equation. 
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4.1 CYP 2E1 activity  
 
Recombinant CYP2E1 activity 
PNP was hydroxylated to 4-nitrocatechol by recombinant CYP2E1. The catalytic activity de-
creased with increasing concentration of quercetin compared to the control (Figure 6a). The 
mode of inhibition was competitive as indicated by a higher Km-value in the presence of in-
hibitor (Figure 6b).     
 
 
 
Figure 6. In vitro inhibition of PNP hydroxylation by quercetin in CYP2E1 human recombinant, ex-
pressed in Saccharomyces cerevisiae. Remaining enzyme activity in percentage in the presence of 16, 
32 and 128 µM of quercetin (a), saturation curve with reaction velocity in different substrate concentra-
tions and Km and Vmax values in presence of different quercetin concentrations (b). 
 
 
  
4 Results 
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Hepatic CYP2E1 activity in human microsomes 
The inhibitory effects of quercetin in human microsomes differed between the two microsome 
pools within the same gender. At a substrate concentration of 200µM, the enzyme activity in 
micrsosomes from pool 1 was not affected by quercetin, irrespective of female or male sam-
ples, and with or without pre-incubation (Figure 7a). When a lower substrate concentration 
was used (20µM PNP), inhibition was observed in male but not female microsomes (Figures 
7a and 7b). In microsome pool 2, enzyme inhibition was observed in both female and male 
samples with 20 µM PNP concentration and in the female microsomes with higher substrate 
concentration. Including a pre-incubation step in the procedure did not increase the level of 
inhibition (Figures 7c and 7). Combining the results from the two microsome pools indicate 
enzyme inhibition in both genders using the lower substrate concentration of 20µM PNP and 
no pre-incubation. Pre-incubation did not further increase the degree of inhibition (Figure 7e 
and 7f). 
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Figure 7. In vitro inhibition by quercetin in human hepatic male and female microsomes containing 
CYP2E1. PNP hydroxylation of male (a) and female (b) human microsomes from pool 1and male (c) 
and female (d) human micrsosomes from pool 2 in two different substrate concentrations. Combined 
results from pool 1 and pool 2 with 20µM substrate concentration (e) and 200µM (f). White bars indi-
cate no pre-incubation and grey bars indicate 15 minutes pre-incubation.  
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A non-competitive mode of inhibition was observed in male microsomes from pool 1(Figure 
8a) and competitive in the microsomes from pool 2 (Figure 8b). For the female samples, no 
inhibition was detected in pool 1 (Figure 8c) and competitive inhibition was seen in micro-
some pool 2 (Figure 8d).  
 
 
     
 
 
 
 
 
 
 
 
Figure 8. Saturation curve of PNP hydroxylation in human hepatic microsomes containing CYP2E1. 
(a) male microsomes from pool 1, (b) male microsomes from Pool 2, (c), female microsomes from pool 
1 and (d) female microsomes from pool 2.   
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PNP hydroxylation by recombinant CYP3A4 
Formation of nitrocatechol from PNP by human recombinant CYP3A4 was not detected in 
the HPLC analysis and therefore no area under the curve could be obtained.   
 
4.2 CYP 3A4 activity 
 
Recombinant CYP3A4 activity 
O-dealkylation of BR was observed in human recombinant CYP3A4, although the catalytic 
activity was not inhibited in the presence of quercetin, myricetin and isorhamnetin compared 
to the control (Figure 9a). The other probe substrate BFC demonstrated O-dealkylation to 
HFC and inhibition in the presence of quercetin and myricetin, but not isorhamnetin. Querce-
tin was the strongest inhibitor (Figure 9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. In vitro inhibition of O-dealkylation of BR (a) and BFC (b) by quercetin, myricetin and iso-
rhamnetin in human recombinant CYP3A4, expressed in Saccharomyces cerevisiae.  
 
 
 
Quercetin inhibited the catalytic activity in human recombinant CYP3A4 competitively (Fig-
ure 10a) and myricetin in a non-competitive manner (Figure 10b).  
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Figure 10. Saturation curve of BFC O-dealkylation by quercetin (a) and myricetin (b) in human recom-
binant CYP3A4 expressed in Saccharomyces cerevisiae. 
 
 
 
Hepatic CYP3A4 activity in human microsomes 
Both female and male human microsomes exhibited decreased catalytic activity in the pres-
ence of quercetin (Figure 11a) and myricetin (Figure 11b) but not isorhamnetin (Figure 
11c). Inhibition was more pronounced in the presence of quercetin than myricetin. There was 
no difference between genders and no effect of pre-incubation, indicating reversible inhibi-
tion.   
 
 
 
 
Figure 11. In vitro inhibition of O-dealkylation of BFC by quercetin (a), myricetin (b) and isorham-
netin (c) in human hepatic male and female microsomes containing CYP3A4. White bars indicate no 
pre-incubation and grey bars indicate 15 minutes pre-incubation. 
 
Quercetin acted as an uncompetitive inhibitor on human microsomal CYP3A4 activity in both 
genders and microsome pools (Figure 12 a-d). Myricetin exhibited a consistent non-competi-
tive mode of inhibition between genders and microsome pools (Figure 13 a-d).  
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Figure 12. Saturation curve of BFC O-dealkylation in human hepatic male (a-b) and female (c-d) mi-
crosomes from two microsome pools, in the presence of quercetin.  
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Figure 13. Saturation curve of BFC O-dealkylation in human hepatic male (a-b) and female (c-d) mi-
crosomes from two microsome pools, in the presence of myricetin.  
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4.3 Summary of results 
The results from the kinetic measurements are summarised in Table 2.  
 
Table 2. Results from inhibition assays of recombinant, male and female CYP2E1 and CYP3A4 from 
two pools respectively in the presence of flavonoids 
 
Enzyme Inhibitor 
Enzyme  
pool 
Sex  
Mode of  
inhibition 
Ki, µM 
CYP2E1 Quercetin Rec - Competitive 52.1 ± 6.31 
  1 M Non-competitive 779.3 ± 373.1  
  2 M Competitive 427 ± 286.3 
  1 F No inhibition  
  2 F Competitive 314.2 ± 361.0 
CYP3A4 Quercetin Rec - Competitive 33.2 ± 3.5 
  1 M Uncompetitive 112 ± 35.9 
  2 M Uncompetitive 32 ± 5 
  1 F Uncompetitive 141 ± 45.6 
  2 F Uncompetitive 75 ± 20.6 
CYP3A4 Myricetin Rec - Non-competitive 74.6 ± 7.9 
  1 M Non-competitive 273 ± 73 
  2 M Non-competitive 534 ± 246 
  1 F Non-competitive 163 ± 29 
  2 F Non-competitive 177 ± 33 
CYP3A4 Isorhamnetin Rec - No inhibition      - 
  1 M No inhibition      - 
  1 F No inhibition      - 
Rec = recombinant, M = male, F = female 
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Modulation of CYP450 activity has a large impact on xenobiotic metabolism. Extensive re-
search in the field of CYP450 regulation has successfully contributed to better predictions of 
food-drug interactions (FDI) although many challenges still remain. Knowledge about gender 
differences in drug metabolism is for instance limited. Flavonoids in our diet are appreciated 
for their positive health effects but may influence drug efficacy by modulating drug metabo-
lising enzymes. The modulation may be gender-dependent, an aspect that should be taken into 
account when health care professionals inform a patient about medications and when estab-
lishing drug dose recommendations. The results of this study can contribute to understanding 
the implication of dietary flavonoids in drug interactions.  
Gender differences in inhibition effects by quercetin on CYP2E1 activity has been identi-
fied in pigs in vitro (Ekstrand et al., 2015). Pig is a widely used animal model in human 
CYP450 studies because the metabolism and disease development in pigs are comparable to 
in humans. Therefore, similar gender differences were expected in this study. That study con-
sidered a 50 % or more decrease in catalytic activity compared to the control might be of 
physiological relevance. Accordingly, decrease in catalytic activity was regarded as inhibition 
if the activity was reduced by at least 50 % in at least one sample within the enzyme pool.   
Because quercetin clearly inhibited recombinant CYP2E1, it was expected to have inhibi-
tory effects on CYP2E1 activity in human microsomes. Surprisingly, no inhibition was ob-
served at the substrate concentration of 200 µM. A theoretical explanation is that the micro-
somes contained other enzymes that metabolise PNP. That is however unlikely because PNP 
is a known selective CYP2E1 substrate (Cederbaum, 2014). Nevertheless, to test this hypoth-
esis, PNP hydroxylation was investigated in human recombinant CYP3A4. Formation of P-
nitrocatechol was not detected, confirming that CYP3A4 is not involved in PNP metabolism. 
Another explanation for the absence of inhibitory effects by quercetin on human microsomal 
CYP2E1 in this experimental set might be too high concentration of substrate used (200 µM). 
Indeed, quercetin inhibited recombinant CYP2E1 in a competitive manner, and this type of 
inhibition can be overcome by using high substrate concentrations. To verify this hypothesis, 
an experiment with lower substrate concentration (20 µM) was set up. In this case, inhibition 
was observed in the microsomes from male but not from female donors. This result is con-
sistent with a similar inhibition study on pigs (Ekstrand et al., 2015). On the contrary, in mi-
crosome pool 2 the degree of inhibition was stronger in female than in male samples. The 
combined results including two microsome pools suggest inhibition in both genders but the 
5 Discussion
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level of inhibition cannot be associated with gender due to the large variations between pool 1 
and pool 2.   
The competitive inhibition observed in male and female samples from pool 2 was in agree-
ment with the theory that PNP has the ability to overpower the inhibitory effect of quercetin. 
However, because the Ki values were much higher than the highest inhibitor concentration 
used, the accuracy of inhibition mode determination is questionable. Increasing the inhibitor 
concentration was not considered since the results would be out of physiologically relevant 
levels. Most probably, quercetin is a weak human CYP2E1 inhibitor and clinically important 
in vivo effects are unlikely. The results from pool 1 further supports this idea, where Ki was 
the highest of all in male and no inhibition was detected in female.  
 
CYP3A4 metabolises a broad spectrum of compounds and accounts for a large portion of xe-
nobiotic metabolism, thus investigating effects of a number of dietary flavonoids is relevant. 
Gender differences in CYP3A activity have been observed in humans and specifically involv-
ing myricetin and isorhamnetin in pigs (Ekstrand et al., 2015), but prior to this study it has not 
been investigated in humans.  
Two probe substrates, BR and BFC, were used to investigate O-dealkylation in recombi-
nant CYP3A4. Because none of the flavonoids inhibited BR metabolism, it was not further 
investigated. Quercetin and myricetin inhibited BFC metabolism in human recombinant 
CYP3A4 as expected. Isorhamnetin had no inhibitory effects despite its similar structure to 
quercetin. It confirms the fact that the number and position of hydroxyl groups in the flavonol 
structure determines the inhibitory capacity.   
Similarly to CYP2E1 inhibition, quercetin inhibited human recombinant CYP3A4 compet-
itively. Myricetin demonstrated non-competitive inhibition, indicating binding to a different 
site of the enzyme compared to quercetin. The results imply that the substrate can overcome 
inhibition by quercetin but not by myricetin. For in vivo relevance, the non-competitive inhib-
itor myricetin would be a more potent inhibitor than the competitive inhibitor quercetin given 
that the drug (substrate) concentration is high enough. However, in this study quercetin was a 
competitive inhibitor only in recombinant CYP3A4 but not in human microsomes which re-
semble in vivo conditions better than recombinant enzyme.  
Both quercetin and myricetin acted as reversible inhibitors in the present study, an irre-
versible mechanism would have a larger impact in vivo because the inhibition is stronger.  
Isorhamnetin had no inhibitory effect. Interestingly, isorhamnetin inhibited CYP3A BFC me-
tabolism in male and female hepatic porcine microsomes (Ekstrand et al. 2015). A species 
difference in CYP3A4 regulation might explain the absence of inhibition by isorhamnetin in 
the present study. Another possibility is that the other member of the CYP3A family, 
CYP3A5, influenced BFC metabolism in the pig study and/or in this study. The exact isoform 
that is inhibited by isorhamnetin remains to be investigated.  
According to the literature, flavonoids possessing many hydroxyl groups are more potent 
CYP450 inhibitors in vitro (Ho et al., 2001; Pang et al., 2012). In this case, quercetin was a 
stronger inhibitor than myricetin of both recombinant and microsomal CYP3A4 enzymes de-
spite one less hydroxyl group. The result suggests that other factors influence differences in 
inhibition potency. Possibly, flavonoids interact differently depending on the choice of sub-
strate and the specific CYP450 isoform. Inhibition by quercetin should be of greater im-
portance in vivo considering it is more prevalent in food than myricetin.   
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The Ki values reveal some fluctuations in degree of inhibition between microsome pools. 
Inhibition by quercetin may seem to be stronger in male CYP3A4 whereas inhibition by myri-
cetin was more pronounced in females indicated by lower Ki values in those samples. How-
ever, the variation was larger between the pools than between genders. Therefore, it cannot be 
concluded that quercetin and myricetin inhibit human CYP3A4 activity in a gender-dependent 
manner.  
 
Taken together, this study confirmed that quercetin inhibits human CYP2E1 activity and 
quercetin and myricetin inhibit human CYP3A4 activity in vitro. In contrast to pigs, there was 
no clear pattern of gender related differences in humans. Genetic or lifestyle factors together 
with weak inhibition effects probably explain the observed variations in enzyme activity be-
tween the samples. Studies on gender-related inhibition mechanisms should therefore include 
enzyme pools from several origins. It is also possible that gender differences exist but cannot 
be detected in the present study due to the other factors influencing enzyme activity. In stud-
ies using animal models, individual characteristics and environmental and dietary factors 
(breed and feed) are strictly controlled. Such control cannot be achieved in human studies.  
Nevertheless, it may explain why gender differences were observed in pigs but not in humans. 
This aspect should be taken into account when applying results from animal studies to human 
CYP450 regulation.  
FDI involving quercetin and myricetin are plausible considering CYP3A4 metabolises 
most drugs. However, the Ki values in the present study were in general higher than the maxi-
mum plasma concentration of bioactive compounds, only quercetin inhibited CYP3A4 at lev-
els relevant in vivo. It should also be noted that in vitro models studying one mechanism 
should be extrapolated in vivo with caution. CYP450 activities are regulated at several levels 
in the body and influenced by both genetic and environmental factors. There may be overlaps 
in bioactivation and detoxification, CYP3A4 can for instance both activate and detoxicate af-
latoxin (Buening et al., 1981). This complexity is also noticeable when the effects of flavo-
noids show contradictory results in short term versus long term exposure. Whether the inves-
tigated flavonoids have the ability to cause clinically relevant FDI must be investigated in 
vivo. In vitro experiments including the present study are useful as an initial approach to pre-
dict FDI.  
It can be argued that use of relatively high concentrations of inhibitor (above the concen-
tration found in circulation) might be regarded as a study limitation. However, Ki values (in 
contrast to IC50) are not dependent on experimental conditions, and provide relevant infor-
mation on potency of the inhibitor independently on the concentration used in the study. In-
deed, in vitro studies aimed to investigate inhibition mechanism commonly use inhibitor con-
centration higher than physiologically relevant to provoke the effect and elucidate the mecha-
nism behind it. The second study limitation is a low number of microsomal pools included in 
the study. Only 2 pools from male and 2 from female donors were used. Even each of these 
pools consisted of microsomes from 20 or more individuals, taken into consideration be-
tween-individual variations, it is difficult to make generalizations about two large subpopula-
tions (human females and males, each comprising about 5 billion individuals). Nevertheless, 
such studies, while preliminary and explorative, are of value and might give new insight into 
interpretation of existing data and suggest new avenues for future research. 
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This study suggests that (1) quercetin reversibly inhibits in vitro activity of human hepatic 
CYP2E1 and (2) quercetin and myricetin but not isorhamnetin reversibly inhibit in vitro activ-
ity of human hepatic CYP3A4. Inter-individual differences in enzyme activity in presence of 
those flavonoids are most likely due to other factors than gender.  
  
6 Conclusions
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8. Appendix: Popular summary 
 
 
What you eat may influence how your body deals with drugs 
 
– and even depend on your gender! 
 
The scientific evidence are clear, piling up your plate with vegetables every day is good for 
you and it prevent diseases. Why are the greens so healthy? Part of the answer could be: Fla-
vonoids. These molecules are not essential nutrients but found in nearly all vegetables. They 
help keeping your cells healthy by for example using their antioxidative power to scavenge 
evil free radicals. What is less desirable about flavonoids is that they can interact with drug 
metabolising enzymes, so called cytochrome P450 enzymes. A well known example is grape-
fruit juice which contains flavonoids that have been shown to inhibit cytochrome P450 en-
zyme activity. An inhibited enzyme is unable to break down drugs or other foreign com-
pounds properly. The consequence may be that the drug loses its effect or in the worst case, 
causes adverse effects.  
I have studied this so called food-drug interaction a bit deeper and found some unexpected 
results. I investigated inhibition of two cytochrome P450 isoforms: CYP2E1 and CYP3A4. 
They are both highly involved in the breakdown of foreign compounds in the liver. In pigs, it 
was previously shown that CYP2E1 and CYP3A4 activity were inhibited by flavonoids dif-
ferently in males compared to females. Since pigs are commonly used as an animal model for 
studying human CYP450 regulation, I was eager to investigate if similar gender-related dif-
ferences exist also in humans.   
The experiment was executed in vitro (in test tubes) where liver enzymes deriving from 
male and female donors were mixed with a flavonoid. Three flavonoids were investigated for 
their inhibitory effects: quercetin, myricetin and isorhamnetin. Quercetin is one of the most 
common flavonoids in our diet, myricetin and isorhamnetin are less present but contribute to 
the overall flavonoid intake. Apples, onions, tea and red wine account for a large portion of 
our dietary sources of flavonoids.   
To my surprise, no gender differences in the degree of enzyme inhibition by flavonoids 
were seen. Instead the inhibition differed greatly between donor pools within the same gen-
der, suggesting that currently unknown factor beyond sex affect the inhibition. Thus, drug 
metabolism is regulated differently in humans compared to in pigs and there must be other 
factors responsible for the inter-individual differences in enzyme activity, for instance genetic 
profile, age or health status of the donors.  
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 Inhibition of CYP2E1 and CYP3A4 was observed in both genders in the presence of quer-
cetin and myricetin but not isorhamnetin. A big question: will the quercetin and myricetin you 
eat impede your ability to break down drugs? According to the results from my study, proba-
bly not, because the inhibition was weak and you would need to eat unrealistic amounts of 
quercetin and myricetin. On the other hand, food contains lots of other flavonoids that may 
also inhibit drug metabolising enzymes. If you are on medication and take additional herbal 
supplements the flavonoid intake will be considerably higher and thereby a food-drug interac-
tion may occur. However, food-drug interactions depend on several other factors, therefore a 
conclusion regarding the effect of quercetin and myricetin in living persons cannot be drawn 
from the results of my research. But it gives a hint of potential food-drug interactions that 
should be further investigated in clinical studies.  
  
 
